Oxxon Therapeutics Limited

Royal Melbourne Institute of Technology

Oxxon Pharmaccines Ltd.

Magdalena Plebanski

Sarah C Gilbert

Andrew James McMichael

Tomas Hanke

Geoffrey L Smith

Tom Blanchard

Adrian V S Hill

Jörg Schneider

J&ouml;rg Schneider

Mutsa Tatenda Madondo

The present disclosure is based on detecting CC chemokine receptor 4 (CCR4) expression on T effector cells to diagnostically or prophylactically predict subjects, in particular those with a gynaecological cancer who will respond to treatment with low dose cyclophosphamide.

Predicting responders to cyclophosphamide therapy

New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumor antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.

Methods and reagents for immunization which generate a CD8 T cell immune response

New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.

Methods and reagents that generate a CD8 T cell immune response

Methods and reagents for vaccination which generate a CD8 T cell immune response

Growing community of inventors

Melbourne, Australia

Magdalena Plebanski